Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics
Open Access
- 17 July 2023
- journal article
- research article
- Published by Springer Nature in BMC Medical Imaging
- Vol. 23 (1) , 1-11
Abstract
Objective: In the present study, we mainly aimed to predict the expression of androgen receptor (AR) in breast cancer (BC) patients by combing radiomic features and clinicopathological factors in a non-invasive machine learning way. Materials and methods: A total of 48 BC patients, who were initially diagnosed by 18F-FDG PET/CT, were retrospectively enrolled in this study. LIFEx software was used to extract radiomic features based on PET and CT data. The most useful predictive features were selected by the LASSO (least absolute shrinkage and selection operator) regression and t-test. Radiomic signatures and clinicopathologic characteristics were incorporated to develop a prediction model using multivariable logistic regression analysis. The receiver operating characteristic (ROC) curve, Hosmer-Lemeshow (H-L) test, and decision curve analysis (DCA) were conducted to assess the predictive efficiency of the model. Results: In the univariate analysis, the metabolic tumor volume (MTV) was significantly correlated with the expression of AR in BC patients (p < 0.05). However, there only existed feeble correlations between estrogen receptor (ER), progesterone receptor (PR), and AR status (p = 0.127, p = 0.061, respectively). Based on the binary logistic regression method, MTV, SHAPE_SphericityCT (CT Sphericity from SHAPE), and GLCM_ContrastCT (CT Contrast from grey-level co-occurrence matrix) were included in the prediction model for AR expression. Among them, GLCM_ContrastCT was an independent predictor of AR status (OR = 9.00, p = 0.018). The area under the curve (AUC) of ROC in this model was 0.832. The p-value of the H-L test was beyond 0.05. Conclusions: A prediction model combining radiomic features and clinicopathological characteristics could be a promising approach to predict the expression of AR and noninvasively screen the BC patients who could benefit from anti-AR regimens.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81601522)
- Medical Youth Talent Project of Jiangsu Province (QNRC2016749)
- Gusu Health Talent Program (GSWS2020013)
- Suzhou people’s Livelihood Science and technology project (SYS2019038)
- Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZK1202127)
- the Open Foundation of Nuclear Medicine Laboratory of Mianyang Central Hospital (2021HYX023)
This publication has 45 references indexed in Scilit:
- The relationship between 18F-FDG metabolic volumetric parameters and clinicopathological factors of breast cancerNuclear Medicine Communications, 2013
- SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin LymphomaClinical Nuclear Medicine, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerCancer Cell, 2011
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1The EMBO Journal, 2011
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health StudyLaboratory Investigation, 2011
- Expression of androgen receptor in breast cancer and its significance as a prognostic factorAnnals of Oncology, 2010
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008
- Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited*Critical Care Medicine, 2007
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004